Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 24-week, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Secukinumab in Controlling Spinal Pain in Patients With Axial Spondyloarthritis

Next Previous
X
Search
Trial Profile

A 24-week, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Secukinumab in Controlling Spinal Pain in Patients With Axial Spondyloarthritis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 22 Dec 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Secukinumab (Primary)
  • Indications Axial spondyloarthritis
  • Focus Therapeutic Use
  • Acronyms SKIPPAIN
  • Sponsors Novartis; Novartis Pharmaceuticals

    • Most Recent Events

    • 09 Nov 2021 Results of post hoc analysis assessing association of the HLA-B27 subtypes and efficacy of secukinumab presented at the ACR Convergence 2021
    • 06 Jun 2020 Primary endpoint (Percentage of Participants With a Spinal Pain Numerical Rating Scale (NRS) Score Below 4 at Week 8) has been met according to the results presented at the 21st Annual Congress of the European League Against Rheumatism
    • 06 Jun 2020 Results from the 24-Week study assessing efficacy and safety of secukinumab (SEC) in reducing spinal pain in patients with axSpA who had an inadequate response to NSAIDs presented at the 21st Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top